Raleigh News & Observer Profiles Trimeris Co-Founder, Chief Executive Dr. Dana Bolognesi
The Raleigh News & Observer today profiles Dr. Dani Bolognesi, co-founder and chief executive of pharmaceutical company Trimeris, which with Roche recently submitted a new drug application to the FDA for Fuzeon, an antiretroviral drug also known as T-20. "We believe there is a good possibility that T-20 could become the cornerstone for a new way of treating advanced (AIDS) patients," Bolognesi said (Ranii, Raleigh News & Observer, 9/19). The full article is available online.This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.